Skip to main content
Premium Trial:

Request an Annual Quote

BD Diagnostics, Lonza Team to Commercialize Assays on BD Max System

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BD Diagnostics and Lonza Group today announced an exclusive licensing and collaboration agreement for the commercialization of Lonza's microCompass molecular assay on the BD Max system.

Under the agreement, Lonza has the right to exclusively co-market globally the BD Max system with the complete microCompass product line in selected fields. In a joint statement, BD and Lonza said the microCompass assays will facilitate rapid detection for total bioburden load, sterility testing, Mycoplasma, and other specific organisms.

The microCompass detection system targets ribosomal RNA for the detection of bacteria, yeast, and molds, according to Lonza's website.

The assays on the BD Max system "will provide an automated platform with same day results for quality control testing in the pharmaceutical and personal care products market segments," the companies said.

Based in Basel, Switzerland, Lonza supplies tools, manufacturing services, and ingredients to the life sciences, pharmaceutical, and healthcare industries.

Terms of the deal were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.